Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VIVUS stock in Canada

Own VIVUS shares in just a few minutes.


VIVUS is a biotechnology business based in the US. VIVUS stocks (VVUS.US) are listed on the NASDAQ and all prices are listed in US Dollars. VIVUS employs 59 staff and has a trailing 12-month revenue of around $73.2 million.

How to buy VIVUS stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: VVUS in this case.
  5. Research VIVUS stocks. The platform should provide the latest information available.
  6. Buy your VIVUS stocks. It's that simple.

VIVUS stock price

Use our graph to track the performance of VVUS stocks over time.

VIVUS stocks at a glance

Information last updated 2021-01-13.
Latest market close$N/A
52-week range$0.0697 - $0.5
50-day moving average $0.122
200-day moving average $0.299
Wall St. target price$1.75
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.596

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy VIVUS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is VIVUS under- or over-valued?

Valuing VIVUS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of VIVUS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.


VIVUS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.8 million.

The EBITDA is a measure of a VIVUS's overall financial performance and is widely used to measure a its profitability.

VIVUS financials

Revenue TTM USD$73.2 million
Gross profit TTM USD$43.8 million
Return on assets TTM -2.2%
Return on equity TTM 0%
Profit margin -39.28%
Book value $-4.93
Market capitalisation USD$8.3 million

TTM: trailing 12 months

How to short and sell VIVUS stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "VVUS.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.0 million VIVUS stocks held short by investors – that's known as VIVUS's "short interest". This figure is 488.8% up from 510,645 last month.

There are a few different ways that this level of interest in shorting VIVUS stocks can be evaluated.

VIVUS's "short interest ratio" (SIR)

VIVUS's "short interest ratio" (SIR) is the quantity of VIVUS stocks currently shorted divided by the average quantity of VIVUS stocks traded daily (recently around 871468.69565217). VIVUS's SIR currently stands at 3.45. In other words for every 100,000 VIVUS stocks traded daily on the market, roughly 3450 stocks are currently held short.

However VIVUS's short interest can also be evaluated against the total number of VIVUS stocks, or, against the total number of tradable VIVUS stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VIVUS's short interest could be expressed as 0.17% of the outstanding stocks (for every 100,000 VIVUS stocks in existence, roughly 170 stocks are currently held short) or 0.1704% of the tradable stocks (for every 100,000 tradable VIVUS stocks, roughly 170 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against VIVUS.

Find out more about how you can short VIVUS stock.

VIVUS stock dividends

We're not expecting VIVUS to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have VIVUS stocks ever split?

VIVUS stocks were split on a 1:10 basis on 11 September 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VIVUS stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for VIVUS stocks which in turn could have impacted VIVUS's stock price.

VIVUS stock price volatility

Over the last 12 months, VIVUS's stocks have ranged in value from as little as $0.0697 up to $0.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while VIVUS's is -0.8493. This would suggest that VIVUS's stocks have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, VIVUS has bucked the trend.

VIVUS overview

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

VIVUS in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site